What is chronic fatigue syndrome? Heterogeneity within an international multicentre study.
Wilson, A, Hickie, I, Hadzi-Pavlovic, D et al. · The Australian and New Zealand journal of psychiatry · 2001 · DOI
Quick Summary
This study looked at 744 people with chronic fatigue across eight countries to see if they formed different groups based on their symptoms. Researchers found two distinct subgroups: a larger group (68%) with less severe illness and fewer psychiatric issues, and a smaller group (32%) whose symptoms looked more like somatoform illness (where psychological factors strongly influence physical symptoms). Importantly, the proportion of people in each group varied dramatically between countries (6-48%), suggesting that how doctors diagnose and classify ME/CFS is not standardized worldwide.
Why It Matters
This study is crucial because it demonstrates that ME/CFS is not a single disease entity but a heterogeneous condition encompassing at least two clinically distinct subgroups. Understanding this variability is essential for designing better clinical trials, identifying which patients might benefit from different treatments, and explaining why international diagnostic criteria produce inconsistent patient populations.
Observed Findings
744 patients across eight international centres completed symptom questionnaires; mean age was 40.8 years, mean illness duration 7.9 years, with a 3:1 female-to-male ratio.
Latent profile analysis identified two distinct subclasses: Class 1 (68% of sample) with younger age, shorter illness duration, and lower psychiatric morbidity; Class 2 (32%) with older age, higher psychiatric burden, and greater functional disability.
The prevalence of Class 2 ranged from 6% to 48% across the eight centres, indicating major variation in patient populations between sites.
Both classes reported high rates of typical CF symptoms (fatigue, neuropsychological dysfunction, sleep disturbance).
Inferred Conclusions
Diagnostic criteria for chronic fatigue and related syndromes do not select a homogeneous patient population, suggesting multiple disease subtypes may be encompassed under the CF diagnosis.
Patient heterogeneity within CF requires substratification for meaningful aetiological and treatment research.
The substantial variation in subclass prevalence between international centres suggests either true geographic/epidemiological differences in CF presentation or inconsistent application of diagnostic criteria across regions.
Remaining Questions
What are the underlying biological or pathophysiological differences between Class 1 and Class 2 patients?
What This Study Does Not Prove
This study does not prove that the two identified subgroups have different biological causes or will respond differently to specific treatments. The cross-sectional design cannot establish whether subclass membership predicts prognosis or treatment outcomes, nor does it clarify whether the variation between centres reflects true epidemiological differences or differences in how doctors apply diagnostic criteria.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Do the identified subclasses predict treatment response, long-term prognosis, or disease progression differently?
Does the variation in subclass prevalence between centres reflect genuine epidemiological differences, diagnostic practice variation, or recruitment bias?
Are the symptom-based subgroups stable over time, or do patients move between classes?